Raymond L. Woosley MD, PhDPresident & Chairman of the Board for CredibleMeds Worldwide; Professor of Medicine & Pharmacology, University of Arizona College of Medicine, Phoenix, Arizona; President, AZCERT
Raymond L. Woosley, M.D., Ph.D. is the founding President and Chairman of the Board for CredibleMeds Worldwide, a non-profit organization dedicated to safe use of medications. He is Emeritus Professor of Medicine and Pharmacology at the University of Arizona College of Medicine in Phoenix, Az and a member of the Sarver Heart Center.
Dr. Woosley received his medical degree from the University of Miami, FL, his doctorate in pharmacology from the University of Louisville, KY, and his bachelor's degree from Western Kentucky University. After an internship and residency in internal medicine, he completed a fellowship in clinical pharmacology at Vanderbilt University before joining the faculty and rising to the rank of Professor of Medicine and Pharmacology.
In 1988, Dr. Woosley was appointed Chairman of the Department of Pharmacology at Georgetown University Medical Center in Washington, D.C. In 2001, Dr. Woosley joined the faculty at The University of Arizona as Vice President of the Arizona Health Sciences Center and the Dean of the College of Medicine. In 2005, he founded Critical Path Institute (C-Path), an independent, non-profit organization created jointly by the U.S. Food and Drug Administration (FDA) and the University of Arizona to help implement the FDA’s Critical Path Initiative and accelerate drug and diagnostic development.
Dr. Woosley’s research has been reported in more than 280 peer-reviewed publications and serve as the basis for eleven patents. For his contributions to medicine, Dr. Woosley has received numerous awards from academic institutions, the Food and Drug Administration and professional societies.
Recent Contributions to PracticeUpdate:
- OncoSupport for Oncocardiology Prescribing
- Anti-Cancer Drug–Induced Life-Threatening Ventricular Arrhythmias
- Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association
- Clinical Efficacy of Hydroxychloroquine in Patients With COVID-19 Pneumonia Who Require Oxygen
- Pharmacologic Treatments for COVID-19
- Association of QT-Prolonging Medications With Causes of Sudden Death
- Cardiac Complications of Chloroquine-Based Therapy
- Androgenic Effects on Ventricular Repolarization
- Impact of High-Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters
- Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases When Adjusting for Patient Characteristics and Comorbidities